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Many human neurological diseases are not currently curable and result in devastating neurologic sequelae. The increasing
availability of induced pluripotent stem cells (iPSCs) derived from adult human somatic cells provides new prospects for
cellreplacement strategies and disease-related basic research in a broad spectrum of human neurologic diseases. Patient-speciﬁc
iPSC-based modeling of neurogenetic and neurodegenerative diseases is an emerging eﬃcient tool for in vitro modeling to
understand disease and to screen for genes and drugs that modify the disease process. With the exponential increase in iPSC
research in recent years, human iPSCs have been successfully derived with diﬀerent technologies and from various cell types.
Although there remain a great deal to learn about patient-speciﬁc iPSC safety, the reprogramming mechanisms, better ways to
direct a speciﬁc reprogramming, ideal cell source for cellular grafts, and the mechanisms by which transplanted stem cells lead
to an enhanced functional recovery and structural reorganization, the discovery of the therapeutic potential of iPSCs oﬀers new
opportunitiesforthetreatmentofincurableneurologicdiseases.However,iPSC-basedtherapeuticstrategiesneedtobethoroughly
evaluated in preclinical animal models of neurological diseases before they can be applied in a clinical setting.
1.Introduction
Human neurological diseases including stroke, neurodegen-
erative disorders, neurotrauma, multiple sclerosis (MS), and
neurodevelopmental disorders are caused by a loss of neu-
rons and glial cells in the brain or spinal cord. They usually
cause morbidity and mortality as well as increase social
and economic burdens of patients and their caregivers [1].
Stroke is one of the leading cause, of death and the primary
cause of morbidity and long-term neurological disability.
The burden of the age-related neurodegenerative diseases
including Alzheimer’s disease (AD), other dementias, and
Parkinson’s disease (PD) is expected to increase dramatically
as the life expectancy and aging population rise worldwide
[2]. Neurodegenerative diseases represent a large group
of heterogeneous disorders characterized by progressive
degenerative loss of speciﬁc neuron subtypes over time:
cortical neurons in AD, dementia with Lewy bodies, or
frontotemporal lobar degeneration, midbrain dopaminergic
neurons in PD, striatal GABAergic neurons and cortical
neurons in Huntington’s disease (HD), cerebellar neurons
in spinocerebellar degeneration, and upper and lower motor
neurons in amyotrophic lateral sclerosis (ALS) [3]. Nonneu-
ronal cells also contribute to the progression of neurodegen-
eration [4]. By contrast, rapid cell loss and destruction of
larger areas of central nervous system (CNS) tissue are seen
in acute lesions, such as in acute ischemic or hemorrhagic
stroke, traumatic brain injury, and spinal cord injury (SCI).
The CNS has limited capacity of regenerating lost tissue in
both cases and require strategies to manage the neurological
deﬁcits caused by the neural tissue destruction. However,
conventionaltherapiesofmanyneurologicaldiseasesprovide
only limited beneﬁt by alleviating certain symptoms. The
chronic use of these drugs is often associated with serious
side eﬀects, and none seems to modify the natural course of
these diseases [5]. Many attempts have been made to develop
neuroprotective drugs to reduce the CNS injury, but the
translation of neuroprotection from experimental therapies
to clinical setting has not been very successful [6]. Although
the adult brain contains small numbers of stem cells in
restricted areas and acute neurological insults stimulate
a basal rate of neural progenitor/precursor proliferation
and diﬀerentiation, they do not contribute signiﬁcantly to
functional recovery. Moreover, adult neurogenesis may be2 Stem Cells International
defective in neurodegenerative diseases [7]. Along with the
development of stem cell technologies, transplantation of
stem cells or their derivatives is a future therapeutic option
for human neurological diseases.
Stem cells are characterized by the ability to renew
themselves (self-renewal) through mitotic cell division and
diﬀerentiate into a diverse range of specialized cell types [8].
These cells are classiﬁed into three types according to their
capacity to diﬀerentiate into specialized cells (potency). The
ﬁrst type is totipotent stem cells, which can be implanted
in the uterus of a living animal and give rise to an entire,
viable organism. The second type is pluripotent stem cells
such as embryonic stem cells (ESCs) that are isolated from
the inner cell mass of blastocysts and induced pluripotent
stem cells (iPSCs) artiﬁcially derived from a nonpluripotent
cell, typically an adult somatic cell through reprogramming.
Pluripotent stem cells can give rise to every cell of an
organism except extraembryonic tissues, such as placenta
[8]. ESCs can become all cell types while adult stem cells
(ASCs) are thought to be limited in diﬀerentiating into
diﬀerent cell types of their tissue of origin. ASCs are found
rarely in mature tissues; therefore, isolation of these cells
from adult tissue is challenging; however, ESCs can be
grown in cell culture. This diﬀerence is crucial for stem
cell replacement therapies because large numbers of cells
are needed for therapeutic applications. The tissues derived
from the patient’s own ASCs are currently believed less likely
to initiate rejection after transplantation. This is signiﬁcant
for solving immune rejection problem of cell replacement
therapies.
The third type is multipotent stem cells that only
generate speciﬁc lineages of cells. Neural stem cells (NSCs)
are multipotent stem cells which are derived from neural
tissues[9].Thesecellsareself-renewinganddiﬀerentiateinto
lineage-speciﬁc neural precursor or progenitor cells (NPCs)
that can give rise to all cell types (neurons, astrocytes, and
oligodendrocyes) of the nervous system through asymmetric
cell division.
The potential applications of stem cell therapies for
treating neurological disorders are enormous. Many labora-
tories are focusing on stem cell treatments for CNS diseases,
including SCI, stroke, ALS, PD, MS, and epilepsy [10–16].
Finally, clinical trial on stem cell therapy for treatment
of neurological disorders was started. Autologous bone
marrow stem cells and mesenchymal stem cells are used
for treatment of amyotrophic lateral sclerosis. In addi-
tion, Geron Corp has started clinical trial using hESC-
derived oligodendrocyte progenitor cells for spinal cord
injury (http://clinicaltrials.gov/). However, ethical concerns,
immunerejectionofgraftedstemcells,andtumorformation
limit the use of human ESCs.
The development of iPSCs in recent years may bypass the
ethicalcontroversiesandrejection problemusing autologous
stem cells, albeit tumor formation stands as a challenge for
cell-replacement therapy [17] .V a r i o u sn e u r a lc e l lt y p e sh a v e
been diﬀerentiated from human or rodent iPSCs generated
by the reprogramming of diﬀerent somatic cells, mainly
skin ﬁbroblasts [18–20]. IPSCs have also been diﬀerenti-
ated to NPCs [21, 22]. In terms of cell morphology and
pluripotency, iPSCs closely resemble ESCs. Several groups
have successfully generated a wide range of iPSCs from
patients with neurodevelopmental and neurodegenerative
diseases [23–25]. Patient-speciﬁc iPSCs overcome the graft
rejection problem providing an autologous cell source.
Genetic correction of patient-speciﬁc iPSCs derived from
the patients with neurogenetic disorders may be required
before the transplantation process. Patient-speciﬁc iPSCs
also represent a valuable tool to dissect the poorly under-
stood mechanisms of neurogenetic and neurodegenerative
diseases. As mentioned above, animal studies alone cannot
unravel the complexities of the human brain and alternative
approaches for disease modeling are required. The failure to
translate the promising results of preclinical neuroprotection
studies to the clinic setting may be due to many factors
including species diﬀerences, brain complexity, age, patient
variability,anddisease-speciﬁcphenotypesthatcannoteasily
be modelled in chosen nonhuman experimental systems
[26, 27]. Cellular modeling studies and chimeric mouse
modelsbasedoniPSCsmayovercomethesebarriers[12,28].
Finally, patient-speciﬁc iPSCs may be most relevant cell
source for drug screening and development as they take
into consideration the patient’s background, the aﬀected cell
type, and the developmental time [24, 29]. In this review,
wesummarizedtherecentadvancementsiniPSCgeneration,
their capacity for diﬀerentiation toward neural lineages, and
iPSC-based transplantation and disease modeling attempts
for neurological diseases.
2. The Generationof iPSCs
2.1. History of iPSCs. IPSCs were initially derived from
mouse embryonic and adult ﬁbroblasts by overexpression
of particular transcription factors, which have become
famousasthe“Yamanakafactors.”Toidentifytranscriptional
regulators capable of reprogramming adult somatic cells into
pluripotent cells, Shinya Yamanaka and his coworkers tested
24 candidate genes which were known to be pluripotency-
associated. After elimination of irrelevant factors, a mini-
mum of four factors remained that were minimally required
to generate mouse iPSCs. These factors are Octamer 3/4
(OCT3/4), SRY-box containing gene 2 (SOX2), cytoplasmic
Myc protein (c-MYC), and Krueppel-like factor 4 (KLF4)
[30]. Speciﬁc ESC markers including Oct3/4, Nanog, E-Ras,
Cripto,Dax1,andZfp296andFgf4wereusedtoconﬁrmthat
pluripotent stem cells were obtained. Only a year later, the
successfulderivationofhiPSCsfromﬁbroblastswasreported
by two diﬀerent groups. Yamanaka’s group used retroviral
vectors encoding OCT4 (also known as Pou5F1), SOX2,
KLF4, and c-MYC while the group of James Thomson used
lentiviral vectors encoding OCT4, SOX2, NANOG, and Lin-
28 to reprogram human ﬁbroblasts for revealed of iPS cells
[31, 32].
2.2. IPSC Technology. Generation of iPCS from somatic cells
is a complicated process that is aﬀe c t e db ym a n yf a c t o r ss u c h
as the source of the initial cell type (type of the somatic
cell used for reprogramming), the particular cocktail ofStem Cells International 3
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Figure 1: Potential applications of patient-speciﬁc pluripotent stem cells in neurological diseases.
factors used for reprogramming, as well as the methods for
delivery of reprogramming factors and culture conditions
(see Figure 1).
2.2.1. Initial Cell Type. In addition to ﬁbroblasts, iPSCs
have now been generated from a large variety of somatic
cell populations. Cell types that have been used for iPSCs
derivation include keratinocytes [33], pancreatic β cells [34],
neural cells [35], mature B and T cells [36], melanocytes [37]
hepatocytes [38], amniotic cells [39, 40], and cells derived
from adipose tissue [41, 42]. However, so far only ﬁbroblasts
have been used to generate iPSCs from patients suﬀering
from neurological diseases.
The inherent diﬀerences among the cell types that have
been used for reprogramming may aﬀect the eﬃciency of
iPSC generation as well as the quality of the generated
iPSCs. For instance, iPSCs derived from mouse embryonic
ﬁbroblasts or hepatocytes exhibit a lower tendency to form
teratomaswhencomparedtoiPSCs derived frommouse tail-
tip ﬁbroblasts [43]. Depending on the cell type used for
reprogramming, reprogramming can be achieved with dif-
ferent eﬃciencies and kinetics. For instance, human primary
keratinocytes reprogrammed 100-fold more eﬃciently and
twofold faster as compared to human ﬁbroblasts [33]. The
kineticsofreprogrammingmayalsovaryfordiﬀerentspecies
if related cell types are used. While 20–25 days were neces-
sary to reprogram human skin ﬁbroblasts, only 8–12 days
were suﬃcient for mouse embryonic ﬁbroblasts. Thus, the
appropriate choice of cell type is a crucial aspect that should
be considered before starting reprogramming experiments:
cells used for reprogramming should be accessible easily
with minimal risk procedures and should be available in
large quantities, in addition to showing high reprogramming
eﬃciencies and iPSC derivation speed.
2.2.2. Reprogramming Factors. Reprogramming factors, such
as OCT4, SOX2, KLF4, c-MYC, Nanog, and LIN28, have
putative roles in ESC development. OCT4 seems to be the
essential reprogramming factor for most initial cell types
[44]. Sox2 synergistically activates Oct-Sox enhancers with
Oct3/4 and regulates the expression of pluripotent stem
cell-speciﬁc genes [45]. However, Sox2 in itself is not an
essential factor for the generation of iPSCs because the
absence of Sox2 can be compensated for by transforming
growth factor β (TGF β) inhibitors or high level of Oct4
[44, 46, 47]. KLF4 is highly expressed in mouse ESCs and
constitutesanimportantfactorforreprogrammingofmouse
somatic cells, yet human ﬁbroblasts could be successfully
reprogrammed in the absence of KLF4 [31]. Much of the
tumorigenic properties of iPSCs might be caused by c-MYC,
which increases the eﬃciency of iPSC generation but also
has ongogenic potential [48]. Instead of c-MYC and KLF,
the factors Nanog and LIN28 were also successfully used for
reprogramming. Nanog appears not to be an essential factor
but it increases the eﬃciency of reprogramming [49].
As many of the current reprogramming factors tend
to endow iPSCs with tumor formation capacity, it is
necessary to ﬁnd new reprogramming factors that lack4 Stem Cells International
tumorigenicity. Speciﬁc chemicals, such BIX-01294 (BIX),
which is a G9a histone methyltransferase (G9a HMTase)
inhibitor [50] 5-aza-2 -deoxycytidine (5-azadC), valproic
acid (VPA), and kenpaullone [51], have been used to replace
oncogenic reprogramming factors [52, 53]. In addition, a
wide range of microRNAs, which are crucially involved
in maintenance, diﬀerentiation, and lineage determination,
have recently been identiﬁed in ESCs. These studies have
shown that microRNAs can contribute to the pluripotency
machinery [54, 55] and that they can facilitate reprogram-
ming synergistically with OCT4, SOX2, and KLF4. Most
importantly, they can replace c-MYC, which has the greatest
tumorigenic potential among reprogramming factors [56].
Recent studies also demonstrated that the p53/p21 pathway
plays an important role in iPSC generation and acts as a
barrier for tumorigenicity [34, 57–60]. It could be shown
that knockdown of p53 results in increased iPSCs genera-
tion eﬃciency. Lin-28, overexpression, which is a negative
regulator of miRNA biogenesis, and p53/p21 pathways also
increased iPSC formation. Therefore, miRNAs involved in
p53 signaling could be used for reprogramming process
without genetic modiﬁcation of the donor cells.
2.2.3. Delivery Method. Retroviral and lentiviral vectors
have been widely used for the delivery of reprogramming
factors. Critical steps in iPSC generation include that repro-
gramming factors can be eﬃciently overexpressed in the
somatic cell type that is chosen for reprogramming and
that expression of the exogenously applied reprogramming
factors is silenced once the cells have been transformed
to a pluripotent stage. Retroviruses eﬃciently infect only
proliferating cells, but expression of reprogramming factors
is silenced in the ESC stage. Lentiviral vectors on the
other hand infect dividing as well as nondividing cells. Yet,
a major disadvantage of lentiviral vectors is that repro-
gramming factors are not eﬃciently silenced once the cells
reach pluripotency. Major disadvantages, which both vector
systems have in common, is that they contain oncogenic
transcription factors and that they randomly integrate into
the genome of infected cells. Adenoviral vectors, which
do not integrate into the infected cells genome have also
been used to deliver reprogramming factors [34]. Yet, their
infection eﬃciency is much lower than retroviral systems.
New strategies have been suggested to generate safe
and less tumorigenic iPSCs by using nonviral methods
or by omitting the oncogenic factors c-MYC and KLF4
[31, 48]. Therefore, attempts have been made to derive
iPSCs by using plasmids rather than viruses [61]o rb y
removal of transgenic sequences from the host genome after
successful reprogramming using recombination-based exci-
sion systems, such as Cre-loxP recombination or PiggyBac
transposition [61–63]. Cre-loxP recombination eﬃciently
removes exogenously delivered reprogramming factors from
their genomic integration sites in iPSCs [63]. An advantage
of the PiggyBac system, however, is that the transposon
is able to excise itself without leaving a footprint at the
integration locus of the reprogrammed cell genome whereas
at least one loxP site remains after Cre-loxP recombination.
Forthisreasons,PiggyBactranspositionmightbesuperiorto
Cre-LoxP recombination.
Viral free methods have been explored to deliver
reprogramming factors by transfecting cells with standard
transfection methods, such as liposomes. However, these
approaches have a limited eﬃciency that may be overcome
through the recent development of polycistronic vectors.
OriP/EBNA1 vectors derived from the Epstein-Barr virus
were used to transfect human somatic cells with episomes
[64]. However, the eﬃciency of iPSC generation was
very low, and reprogramming factors expression gradually
decreased when expressed from OriP/EBNA1 episomal vec-
tor transfection.
Other nonviral delivery methods including RNA and
protein transfection have also been tried for iPS generation.
Recently, Warren et al. could show that human somatic
cells converted to iPSCs by using synthetic mRNAs [65].
This system is simple and eﬃcient, but again has increased
oncogenic potential due to relative high levels of c-MYC
expression. Protein transduction may be an alternative
way for iPSCs generation without genetic interference.
Drosophila antennapedia peptide, the herpes simplex virus
VP22 protein, and the HIV TAT protein transduction motif
are the most widely used proteins in this approach [66].
Besidesthose,smallmoleculecarriers(SMoCs)[67]andcell-
penetrating peptides (CPP) [68, 69] have also been used to
carry reprogramming factor proteins into host cells [70].
2.2.4. Culture Conditions. A major problem in iPSC genera-
tion for therapeutical us is that xenogenic products are used
at multiple steps in current protocols for iPSC generation
and maintenance. For instance, fetal bovine serum (FBS)
containing media processed with animal-derived enzymes
(e.g., trypsin) are used to maintain primary cultures of
the human somatic cells that are to be reprogrammed.
Xenogenic contamination might also occur when viruses are
used to transduce somatic cells with reprogramming factors.
Feeder cell layers of mitotically inactivated mouse embryonic
ﬁbroblasts plated on gelatin of animal origin and culture
media containing serumsubstitutes, suchas knockout serum
replacement (KO-SR), are used for the growth and selection
of reprogrammed iPSC colonies and their maintenance.
Therefore, xeno-free alternatives to those products have been
tested for the derivation and maintenance of human embry-
onic stem cell (hESC) lines [19, 71]. Recently, immortalized
human ﬁbroblast lines have been shown to be permissive
for iPSC generation [72], and reprogramming of human
ﬁbroblasts under xeno-free conditions could be achieved at
eﬃciencies that were similar to conditions when animal-
derived products were used [73].
For all these reasons, strict quality control procedures
related to the culture of iPSCs are crucial, especially if the
generated iPSCs are intended to be delivered to human
subjects. Another common problem in cell culture work
is mycoplasma contamination, and contamination tests
should be performed on iPSCs and all other cells that were
used during their derivation. This control is particularly
critical because mycoplasma infection has been shown to
dramaticallychangestemcellviabilityandfunction.Another
problem is the tendency of cells in culture to become
genetically instable, and karyotype analysis on iPSCs shouldStem Cells International 5
be performed, particularly after extended serial passaging
[23].
2.2.5. Validation of iPSCs. Patient-speciﬁc iPSCs should
validated and subjected to rigorous quality controls before
deemed pluripotent. Therefore, a test for pluripotency
should be performed by testing for the presence of pluripo-
tency markers in human iPSCs that will be used in
cell theraoy. These markers include cytoplasmic alkaline
phosphatase and cell surface markers such as the stage-
speciﬁc embryonic antigens (SSEA) SSEA-3, SSEA-4 and
the tumor recognition antigens (TRA) TRA-1–60 and TRA-
1–81. Immunocytochemistry and ﬂow cytometry can be
routinely used to assay the expression of these pluripotency
markers. Pluripotent iPSCs and hESCs also endogenously
express the nuclear transcription factors OCT4, SOX2,
and NANOG and endogenous expression of these factors
must be distinguished from expression of the exogenously
introduced factors that might have been delivered during the
reprogramming procedure. Oligonucleotide primers speciﬁc
for either the endogenous or exogenous factors can be
designed and used in RT-PCR in order to solve this problem.
In addition, gene expression proﬁling can also be used
to test for the presence of pluripotency markers. Most
of the characteristic genes, which are associated with the
pluripotent state, have been identiﬁed by microarray studies
using hESCs. Therefore, the expression of these pluripotency
markers can be analyzed by performing multiple standard
quantitative RT-PCR, specialized RT-PCR arrays, or by using
microarray platforms. Important for cell replacement ther-
apy, the diﬀerentiation potential of iPSCs and hESCs should
also be tested. A simple method to check for pluripotency
of iPSCs and hESCs is to test for their ability to form
embryoid bodies (EBs) in vitro while a more stringent test
would comprise an examination of their teratoma formation
potential in vivo [23].
2.2.6.NeuralDiﬀerentiationfromiPSCs. TheuseofiPSCsfor
the treatment of neurological disorders requires that iPSCs
can diﬀerentiate into the relevant neuronal subtypes that
should be replaced or repaired by the therapy. The extended
knowledge of neural development has provided a good
opportunitytogenerateneuralcellsfromiPSCs,andneurons
of diﬀerent parts of the neural tube have been successfully
generated, including spinal motoneurons [74], midbrain
dopaminergic neurons [75], spinal cord interneurons [76],
purkinje and granule cells of the cerebellum [77, 78],
hypothalamic neurons [79], and cortical pyramidal neurons
[80, 81]. Those studies have revealed that ESC neurogenesis,
much like in neural induction during embryonic devel-
opment, is regulated by the coordinated actions of bone
morphogenetic proteins (BMP), Wnt, ﬁbroblast growth
factor (FGF), and insulin-like growth factors (IGF) signaling
pathways. Neural induction in ESCs and speciﬁcation of
ESC-derived neural progenitors follow the same order of
signals as in vivo, and proper timing of exposure to these
factors can give rise to well-deﬁned neuronal populations.
S e v e r a lg r o u p sh a v er e p o r t e din vitro diﬀerentiation of
neural cells from human iPSCs using the embryoid body
formation method. The earliest recognizable cell type in the
neural lineage is the neural ectoderm. The diﬀerentiation of
human iPSCs including patient-speciﬁc iPSCs into neural
ectoderm cells [82] has been demonstrated by positive
staining for NES [83], increased expression of PAX6, and
neural cell adhesion molecule mRNAs [31, 84]. Yamanaka’s
group could also show that human iPSCs can diﬀerentiate
into βIII-TUBULIN-positive neurons as well as GFAP-
positive astrocytes [32, 48].
2.2.7. The Equivalency of iPSC to ESC. IPSCs and ESCs share
major properties such as self-renewal and pluripotency; that
is, they are capable of producing cells of all kind of tissues
and organs [40, 85]. IPSCs and ESCs have a similar pheno-
type because their gene expression patterns and epigenetic
makeup are highly similar [86, 87]. Recent studies, which
compare human and mouse ESCs, however, have shown that
being phenotypically similar does not necessarily include
that they are functionally equivalent. Because pluripotency
is controlled by diﬀerent signaling pathways in human and
mouse ESCs, they cannot be considered to be functionally
equivalent [88] .O nt h ec o n t r a r y ,h o w e v e r ,i th a sb e e n
demonstrated that human iPSCs and hESCs might rely on
the identical signaling pathways [89] in order to ensure their
pluripotency and that early cell fate decisions are controlled
by similar mechanisms [90]. Therefore, these studies suggest
that human iPSCs and ESCs are functionally equivalent.
3. IPSCsDerivedfrom the Patientswith
NeurologicalDiseases
The generation of human iPSCs oﬀers new approaches to
model and cure human diseases. In 2008, Park et al., for
the ﬁrst time, created patient- as well as disease-speciﬁc
iPSCs from skin ﬁbroblasts of patients that suﬀered from
a variety of genetic diseases, including adenosine deami-
nase deﬁciency-related severe combined immunodeﬁciency,
Gaucher disease type III, Duchenne (DMD) and Becker
muscular dystrophy (BMD), Parkinson disease (PD), Hunt-
ington’s the disease (HD), juvenile-onset, type 1 diabetes
mellitus, Down syndrome (DS)/trisomy 21, and the carrier
stateofLesch-Nyhansyndrome[82].Similarly,bonemarrow
mesenchymal cells of a male patient with Shwachman-
Bodian-Diamond syndrome were used to create iPSCs.
Disease-speciﬁc genetic defects have been characterized in
iPSCs derived from patients suﬀering from monogenic
diseases. Patient-speciﬁc iPSCs share major morphological,
molecular, and developmental features with human ESCs,
they form teratomas in immunodeﬁcient mice and show
multilineage diﬀerentiation capacity [82]. The diﬀerentia-
tion of patient-speciﬁc iPSCs into speciﬁc neural cell types,
however, has not been investigated in the study by Park et
al.(2008).Subsequently,severalgroupshavealsosuccessfully
generated a wide range of iPSCs from patients with genetic,
metabolic, cardiac, and hematological diseases [101, 102]. A
list of neurological disorders, including neurodevelopmental
and neurodegenerative diseases, that were used to generate
patient-speciﬁc iPCSc is summarized in Table 1.6 Stem Cells International
Table 1: Patient-speciﬁc pluripotent stem cells in neurological diseases.
Disease Disease gene/molecular defect Generated neural cell type
Disease-speciﬁc
genotype/phenotype in iPSCs
and/or generated neural cells
Reference
SMA (type 1) SMN Motor neuron Decreased neuronal survival Ebert et al. [91]
FD IKBKAP NCPC Impaired neuronal
diﬀerentiation and migration
Lee et al. [92]
HD Huntingtin Striatal neuron Enhanced caspase activity and
neurotoxicity
Zhang et al. [93]
NSC
Upon growth factor
deprivation in iPSC-derived
NSCs 72 CAG repeats in iPSCs
Park et al. [82]
FA Frataxin — GAA·TTC triplet repeat
instability in iPSCs
Ku et al. [94]
ALS Multifactorial Motor neuron L144F polymorphism of
SOD1 gene
Dimos et al. [95]
PD Multifactorial vmDopaminergic neuron Not evaluated Cooper et al. [96]
Dopaminergic neuron Not evaluated Soldner et al. [62]
Not evaluated Park et al. [82]
AS UBE3A Neuron/astrocyte UBE3A repression Chamberlain et al. [97]
PWS Imprinting defect Neuron/astrocyte-like Decreased SNORD116
expression in iPSCs
Yang et al. [98]
— Methylation imprint in iPSCs Chamberlain et al. [97]
DS Trisomy 21 — Decreased tumor formation
by iPSCs
Baek et al. [99]
Trisomy 21 in iPSCs Park et al. [82]
BMD Dystrophin — Not shown Park et al. [82]
DMD Dystrophin — Deletion of exons 45–52 in
iPSCs
Park et al. [82]
— Deletion of exons 4–43 in
iPSCs
Kazuki et al. [100]
Amyotrophic lateral sclerosis (ALS), Angelman syndrome (AS), Becker muscular dystrophy (BMD), Down syndrome (DS), Duchenne muscular dystrophy
(DMD), familial dysautonomia (FD), Friedreich’s ataxia (FA), Huntington disease (HD), I-κ-B kinase complex-associated protein (IKBKAP), neural
crest precursor cell (NCPC), neural stem cell (NSC), Parkinson disease (PD), Prader-Willi syndrome (PWS), small nucleolar RNA (snoRNA) HBII-85
(SNORD116), survival motor neuron (SMN), superoxide dismutase 1 (SOD1), spinal muscular atrophy (SMA), ubiquitin protein ligase E3A (UBE3A), and
ventral midbrain (vm).
3.1. Early-Onset Genetic Neurological Disorders. Certain
monogenic neurological diseases are characterized by young
childhood-onset, such as spinal muscular atrophy (SMA)
and familial dysautonomia (FD). These diseases are auto-
somal recessive and are caused by the loss of function
of a single speciﬁc gene, and rapid disease progression
occurs within the ﬁrst years of life. SMA is a group of
autosomal recessive diseases caused by loss or mutations in
the survival motor neuron (SMN) genes [24]. SMA type
1 is caused by mutations in the survival motor neuron1
gene (SMN1), leading to reduced SMN protein levels and
a selective dysfunction of motor neurons, although the
pathogenesis of the disease and its speciﬁcity to the spinal
motor neurons are not fully understood. Recently, Ebert et
al. successfully established iPSCs from a type 1 SMA patient
and his unaﬀected mother, and showed that patient-speciﬁc
iPSCs expanded robustly in culture and retained the capacity
to generate diﬀerentiated neural tissue and motor neurons
while maintaining the disease genotype and phenotype of
selective motor neuron death [91]. Although the behavior of
these cells in vivo remains to be identiﬁed, patient-speciﬁc
iPSCs represent a novel and promising resource to study the
mechanisms of SMA. Further functional studies, including
electrophysiological experiments and coculture studies with
motor neurons derived from SMA-iPSCs and muscle ﬁbers,
are needed. It has been proposed that more iPSC clones from
other patients and control cases will reduce the concern that
the observed phenotype could be a consequence of intrinsic
iPSC variability [24, 91].
Lee and coworkers recently established iPSCs from
anotherfatalneurodegenerativedisease,FD,thatresultsfrom
an aberrant splicing of the IkB kinase complex-associated
protein (IKBKAP) [92]. FD, also known as hereditary
sensory and autonomic neuropathy III (HSAN-III) or Riley-
Day syndrome, is a sensory and autonomic neuropathy that
aﬀectsthedevelopmentandsurvivalofsensory,sympathetic,
and parasympathetic neurons [103]. Lee et al. showed
that iPSC-derived neural crest precursor cells from three
FD patients had low levels of IKBKAP expression and
exhibit neuronal diﬀerentiation and migration defects [92].Stem Cells International 7
In addition, comparative transcriptome analyses revealed
signiﬁcantly reduced expression levels of several transcripts
in FD-derived iPSCs when compared to human control
iPSCs. Among the candidates validated by quantitative PCR,
many genes were involved in peripheral neurogenesis and
neuronal diﬀerentiation [92].
Ku et al. have reported the derivation of patient-speciﬁc
iPSCs from skin ﬁbroblasts of two Friedreich’s ataxia patients
by transcription factor reprogramming [94]. Friedreich’s
ataxia is an autosomal recessive neurodegenerative disease
caused by a mutation in the FXN gene encoding the mito-
chondrial protein frataxin [104]. The neurodegeneration
in the dorsal root ganglia, accompanied by the loss of
peripheral sensory nerve ﬁbres and degeneration of the
posterior columns of the spinal cord, is a hallmark of the
diseaseandisresponsibleforthetypicalcombinationofsigns
and symptoms that are speciﬁc to Friedreich’s ataxia [105].
The mutant FXN gene contains GAA·TTC triplet repeat
hyperexpansions within the ﬁrst intron. Long GAA·TTC
repeats cause heterochromatin-mediated gene silencing and
loss of frataxin expression in FD patients. Ku et al. showed
that FXN gene repression is maintained in FD patient-
speciﬁc iPSCs derived from ﬁbroblasts [94]. Using these
cells, Ku et al. showed that the silencing of the mismatch
repair enzyme MSH2 prevents repeat expansion, providing
a possible molecular explanation for repeat instability in
Friedreich’s ataxia.
Patient-speciﬁc iPSCs have also been derived from dis-
eases in which genomic imprinting is aﬀected and which are
a c c o m p a n i e db yn e u r o l o g i c a ls y m p t o m s[ 97, 98]. Angelman
syndrome results from the loss of the maternal copy of the
E3 ubiquitin ligase (UBE3A) and goes along with mental
retardation,seizures,sleepdisturbance,andataxia.Thesister
syndrome, Prader-Willi syndrome, is caused by a similar
loss of paternally inherited genes and maternal imprinting.
This syndrome is a neurological disorder characterized by
neonatal hypotonia, failure to thrive, hypogonadism and
short stature, mild to moderate mental retardation, and
compulsive hyperphagia in early childhood that leads to
morbid obesity [98]. Chamberlain et al. derived iPSCs
from patients with Angelman and Prader-Willi syndrome,
providing a promising cellular model of these neuroge-
netic disorders [97]. The authors were able to diﬀerentiate
functional neurons from a total of three iPSC lines. IPSC
derived from the patients with Prader-Willi syndrome retain
high level of DNA methylation in the imprinting center
of the maternal allele and show concomitant reduced
expression of the disease-associated small nucleolar RNA
HBII-85/SNORD116 [98].
TworesearchgroupshaverecentlyestablishediPSCsfrom
patients with Down’s syndrome (DS), a frequent genetic
cause of mental retardation in humans, occurring in 1 out
of 700 births [82, 99]. This syndrome is an autosomal
chromosomal abnormality caused by the presence of an
additional third copy of chromosome 21 and is also known
as trisomy 21. IPSCs derived from skin ﬁbroblasts of two
DS patients showed the characteristic trisomy 21 anomaly
[82]. Baek et al. injected iPSCs generated from a DS indi-
vidual into an immunodeﬁcient mouse [99]. The resulting
teratomas show trisomy 21, which results in suppression
of angiogenesis while control mice had considerable tumor
growth due to blood vessel formation. These experiments
provide an explanation for the relatively low incidence of
most solid tumors in DS patients. Consistently, the expres-
sion of DS candidate region-1 (DSCR1), which encodes a
protein that suppresses vascular endothelial growth factor-
mediated angiogenic signaling by the calcineurin pathway,
was increased in DS tissues [99].
3.2. Late-Onset Genetic Neurological Disorders. In addition
to early-onset genetic disorders, patient-speciﬁc iPSCs have
also been obtained from patients with late-onset neurode-
generative diseases including HD, PD, and ALS. Interest-
ingly, ﬁbroblasts obtained from elderly patients could be
reprogrammed with similar eﬃciency as those obtained
from younger patients [62, 95]. Park et al. showed the
presence of expanded (CAG)n polyglutamine triplet repeat
sequences in the proximal portion of the huntingtin (Htt)
gene in iPSCs derived from a HD patient [82]. HD is a
dominantly inherited fatal neurodegenerative disease caused
by a CAG repeat expansion in the ﬁrst exon of the gene Htt.
The genotype and phenotype of neurons derived from HD
patient-speciﬁc iPSCs was recently extensively investigated
by Zhang et al. [93]. Currently there is no cure for HD. The
HD-speciﬁc iPSC line studied by Zhang et al. was originally
derived from an HD patient with a 72-repeat CAG tract
in the study by Park et al. [82]. HD-speciﬁc iPSCs can
be diﬀerentiated to NSCs and further to striatal neurons
exhibiting the genotypic and phenotypic changes that are
speciﬁc to HD [93] .T h ee n d o g e n o u sH Dm u t a t i o np e r s i s t e d
in all cell types, and the stability of the CAG trinucleotide
repeats in NSCs and striatal-diﬀerentiated neurons derived
from iPSCs ensures the consistency and reproducibility for
the use of these cells as HD model. NSCs derived from
HD-speciﬁc iPSCs show enhanced caspase 3/7 activity and
cellular toxicity upon growth factor withdrawal compared to
normal control NSCs [93].
In contrast to HD, the vast majority of ALS and PD cases
are sporadic. Yet, the study of rare familial forms of these
neurodegenerative diseases can also provide valuable infor-
mation about the pathogenesis of age-related sporadic forms
of ALS and PD as both familial and sporadic cases share
common phenotypic traits, such as the involvement and loss
of speciﬁc neuron subpopulations. ALS is a progressive fatal
neurodegenerative disease aﬀecting upper and lower motor
neurons. In 2008, Dimos et al. generated patient-speciﬁc
iPSCs derived from skin ﬁbroblasts of two elderly sisters with
ALS-associated mutations in the gene encoding superoxide
dismutase (SOD1) [95]. One of the cases clinically exhibited
the signs of ALS. Using an in vitro diﬀerentiation protocol,
the authors diﬀerentiated motor neurons from embryoid
bodies formed by patient-speciﬁc iPSCs. Within the same
culturesglialcellscouldalsobeidentiﬁed.Genotypicanalysis
revealed a L144F polymorphism in SOD1 gene both in
patient-speciﬁc iPSCs and iPSC-derived motor neurons
[95]. However, disease-speciﬁc phenotypic pathologies in
the diﬀerentiated neurons and glial cells remain to be
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ﬁbroblasts of a sporadic PD patient by Park et al., another
recent study showed the generation of iPSCs from the skin
biopsy materials of ﬁve sporadic PD patients [62, 82]. The
authors were successful in diﬀerentiating the iPSC lines into
human dopaminergic neurons. Using the same iPSC lines, a
more recent study has further optimized the diﬀerentiation
protocol to obtain human ventral midbrain dopaminergic
neurons [96].
4.ModelingNeurologicalDiseases with
Patient-SpeciﬁciPSCs
In neurology, most of the current knowledge about disease-
related neuronal phenotypes is gathered from postmortem
studies because obtaining live brain tissue is limited. This
creates a problem for understanding disease progression
and development, because postmortem samples only rep-
resent the end-stage of the disease. In addition, aspects
of the pathology that are observed in these samples could
be secondary and not faithfully reﬂect the exact disease
p h e n o t y p eo nac e l l u l a rl e v e l[ 24]. Therefore, knowledge of
human neuropathological abnormalities and their progres-
sion during the course of a disease is similarly limited. Inter-
species diﬀerences make it diﬃcult to accurately simulate
human neurological diseases in animal models. Therefore,
disease modeling by recapitulating the diseases phenotype
in vitro and in deﬁned cell populations is an important
advancement and would make it possible to understand
cellular mechanisms of the neurodegenerative diseases [23].
Reprogramming of somatic cells which are taken from rare,
monogenic neurogenetic disorders or familial and sporadic
multifactorial neurodegenerative disease backgrounds oﬀer
a unique opportunity for patient-speciﬁc studies and for
studies on the cellular level in vitro [25, 82]. Naturally,
investigation of multifactorial diseases has been more chal-
lenging because of their more complex genetic backgrounds
and because they are usually inﬂuenced by environmental
factors [24]. Many studies have been reported that include
the generation of iPSCs-derived neural cells but only few of
them were able to recapitulate the phenotype of a disease in
the iPSC-derived neural population.
Incomplete disease modeling using iPSCs has ﬁrst been
reported in autosomal recessive neurodegenerative diseases
by Ebert et al. it showed that SMA-iPSCs-derived neural cells
undergo selective neuronal death, which could be reversed
by adding the compounds known to raise the production of
SMN protein [91]. However, fully functional neurons show-
ing the disease phenotype could not be produced. Although
these cells show a decreased amount of mRNA transcripts,
reduced SMN protein levels could not be demonstrated
in adult cell type. This study is a proof-of-concept study
for iPSCs technology but an incomplete disease model in
itself [91]. FD results from an aberrant splicing of IKBKAP
transcripts, which has recently been modeled using patient-
speciﬁc iPSCs [92]. In this study defective IKBKAP splicing
decreased neurogenesis and aﬀected migration of iPSCs
derived neural precursors. However, similar to the SMA
study, decreased protein production could not be observed
in fully mature cell [92].
Subsequently, iPSCs have also been established from the
patients with late-onset neurodegenerative diseases. Dimos
etal.successfullydirecteddiﬀerentiationofiPSCswhichwere
generated from cells of two familial ALS patients. The iPSCs
were able to diﬀerentiate into motor neurons expressing
appropriate motor neuron markers such as Hb9 and ISLET
but no disease phenotype was observed [95]. The generation
of patient-speciﬁc iPSCs from sporadic ALS cases has not
been reported so far. Jaenish and his colleagues reported
that dopaminergic neurons could be derived from iPSCs that
were generated from sporadic PD patients [62]. However,
no gross loss of dopaminergic neurons was reported, indi-
cating that additional stressors may be required to reveal
phenotypes of neurodegenerative diseases with late-onset. A
vast majority of PD cases are sporadic; however, the study
of rare family forms of the disease that are associated with
speciﬁc gene mutations can provide valuable information on
the general disease mechanisms, which might be relevant for
sporadic forms aswell. Diﬀerent genes including α-synuclein
(SNCA),PARKIN,andDJ-1havebeenassociatedwithfamil-
ial PD cases. It would be interesting to see whether iPSCs
or their derivatives generated from familial PD cases could
exhibit speciﬁc disease genotypes and phenotypes in vitro.
5. Drug Screening with Patient-Speciﬁc iPSCs
andTheir Derivatives
Another potential impact of human iPSC research is the use
of patient-speciﬁc cells for the process of drug discovery.
The ability to analyze drug responses in vitro provides an
invaluable tool for testing candidate neurotherapeutic agents
in patient-speciﬁc iPSC-based disease models [106].
The drug discovery process is time consuming and costly
because of high attrition rates and protracted research and
development cycles. Many candidate drugs that have signiﬁ-
cant eﬀect on animal models fail to show signiﬁcant beneﬁts
in clinical trials [29]. Tests based on human cells would
avoid potential interspecies variations and, as such, predict
more precisely any potential adverse eﬀects in humans [24].
High-throughputdrugscreeningusingimmortalizedhuman
cell lines was a major step forward for the development
of new drug therapies. Although immortalized are cheap,
easy to grow, and reproducible, they may not accurately
reﬂect the normal physiological conditions [29]. Therefore,
human iPSCs and their diﬀerentiated derivatives hold a great
promise for gaining new insights into the mechanisms of
humanneurologicaldiseasesandfordrugscreening.Patient-
speciﬁciPSCspossesasigniﬁcantadvantageastheyfaithfully
reﬂectthepatient’sgeneticbackground,theaﬀectedcelltype,
as well as the developmental time [24].
The feasibility of exploring the therapeutic action of
candidate drugs for human neurological diseases in vitro
using patient-speciﬁc iPSCs has been demostrated. A study
by Ebert et al. provides a proof-of-principle for the use
of iPSC in drug screening by using the SMA patient-
speciﬁc iPSCs or their derivatives [91]. In this study iPSC-
derived motor neurons were treated with valproic acid or
tobramycin, two drugs that increased the expression of both
full-lengthandtruncatedversionsoftheSMNprotein.SMA-
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a signiﬁcant increase in SMN protein levels compared to
untreated control cells. This exciting observation suggests
that similar approaches could be used to test the eﬃcacy
of candidate drugs before they are administered to patients.
Subsequently, Lee et al. (2009) tested the eﬀects of three
candidate drugs on aberrant IKBKAP splicing, neuronal
diﬀerentiation, and migration defects in FD-speciﬁc iPSCs
and neural crest precursor cells (NCPCs) derived from
these iPSCs [92]. The plant hormone kinetin resulted in
a marked reduction of the mutant IKBKAP splice form
whereas epigallocatechin gallate or tocotrienol exposure did
notprovidesigniﬁcantimprovements.Thekinetin-mediated
decrease in mutant IKBKAP was associated with an increase
in correctly spliced IKBKAP levels and the ratio of normal
to mutant transcript [92]. Although short-term (1 or 5
day) kinetin treatment of FD-iPSC-derived NCPCs did not
result in a prominent increase in neuronal diﬀerentiation
or improve neuronal migration, long-term (28 days) kinetin
treatment induced a signiﬁcant increase in the percentage
of diﬀerentiating neurons. However, kinetin had no eﬀect
on NCPC migration suggesting an incomplete restoration
of the disease phenotype [92]. These results show the great
potential of patient-speciﬁc iPSCs in drug screening for the
treatment of human neurological diseases.
Possible toxic eﬀects of candidate drugs are often missed
in rodent cells and animal models in general due to speciﬁc
interactions with human biological processes that cannot be
accurately recapitulated in these assay systems [29]. Human
iPSCsarethusalsoanimportanttoolfortoxicologicaltesting
of drugs and for the identiﬁcation of environmental factors
[107]. The current challenge is the lack of a gold standard for
human cell-based toxicity tests. The lessons learnt from the
hESC-based assays may be valuable for the standardization
and optimization of iPSC-based neurotoxicologic assays. In
this context, the choice of reprogramming factors used to
reprogram cells, options for reprogramming factor delivery,
selection of target cell type, conditions for reprogramming
of cells, and culture conditions should be thoughtfully
considered for the establishment of iPSCs-based toxicity
tests [107]. Beside establishing standards for quality control,
technicalchallengessuchasloweﬃciency,highheterogeneity
and variability, and time-consuming and costly methods for
the generation and maintenance of iPSCs need to be solved.
It also remains to be determined whether artiﬁcial in vitro
systems such as iPSC-based assays can actually faithfully
predict the toxicity of drugs in a complex in vivo setting [29].
6.TherapeuticPotentialofPatient-Speciﬁc
iPSCsinNeurologicalDiseases
As summarized above, the recent advances in deriving
iPSCs from patients oﬀer new and exciting possibilities for
biomedical research and clinical applications, as these cells
could be used for autologous transplantation in neurological
diseases.
There are two main strategies for using iPSCs to treat
neurological disorders. The ﬁrst is to produce new neurons
to replace those lost during disease progression. The second
is to produce glial cells that could protect neurons from
ongoing degeneration by expressing and secreting critical
humoral factors, for example, growth factors. Park et al.
showed that growth factor-expressing glial cells can con-
tribute to motor neuron protection in ALS mice. This study
underlines the important fact that (micro-) environmental
conditions should also be considered in cell-based therapies
and might include the delivery of glial cell types along with
neurons.
As summarized before, iPSCs derived from patients
with chronic neurological diseases can be successfully dif-
ferentiated into diﬀerent types of neural cells, neuronal
subtypes, or neural cell precursors in vitro [13, 62, 91–
93, 95, 115]. In addition, the results of in vivo experimental
transplantation studies suggest that engrafted neurospheres
derived from human iPSCs are able to diﬀerentiate to
various types of neural cells such as neurons, astrocytes, and
oligodendrocytes in the central nervous system of embryonic
mice [114]. Upon transplantation into the fetal mouse brain,
NPCs derived from mouse iPSCs migrate into various brain
regions and diﬀerentiate into glia and neurons, including
glutamatergic, GABAergic, and catecholaminergic subtypes
[110]. IPSCs or their derivatives are thus capable to integrate
into preexisting functional neuronal circuitries in the CNS.
Electrophysiological recordings and morphological analysis
demonstrate that the grafted neurons display normal neu-
ronal activity and are functionally integrated into the host
brain. These results support the idea that the transplantation
of iPSCs or iPSC-derived NSCs could be eﬃciently used to
treat chronic neurological diseases or for neurorestoration
in the chronic phase of acute neurological diseases such as
stroke and neurotrauma. Indeed, several recent studies that
tested this idea in experimental models of stroke, PD, and
SCI indicate the therapeutic potential of human or rodent
iPSCs (Table 2). The results of a few studies also suggest
that transplanted iPSCs or their derivatives are capable of
participating and integrating with the preexisting functional
neuronal circuitries in the CNS.
Fetal tissue transplantation for PD has given way to
cell replacement therapy for neurodegenerative diseases
[116]. PD is mainly caused by the degeneration of mes-
encephalic substantia nigra dopaminergic neurons and a
progressive loss of dopaminergic neurotransmission in the
caudate and putamen of the neostriatum [117]. Patients
exhibit motor dysfunction such as tremor, rigidity, and
bradykinesia, as well as disturbances in sleep and cognition.
To date, L-DOPA and other dopamine agonists provide
relief of major symptoms but are only eﬀective in the
early course of the disease. Deep brain stimulation of the
subthalamic nuclei is an additional therapeutic option for
PD patients, but requires surgical intervention. While all of
these treatments provide symptomatic relief, none of them
is able to change the course of the disease or inhibit its
progression[5,117].Thus,thereisaclearneedforrestorative
and regenerative approaches, including cell-based therapies.
The restoration of dopaminergic neurons in patients with
PD via implantation of embryonic midbrain tissue was
taken from animal experiments to clinical applications, but
showed only a limited eﬃcacy. Recent studies from several10 Stem Cells International
Table 2: iPSC-based cell-replacement therapy in preclinical animal models of neurological diseases.
Disease Species Model Transplanted cells Delivery route Outcome Reference
PD
Rat 6-OHDA mbDA PGCs derived
from hiPSCs Transplantation
Long-term survival
Diﬀerentiation to DA
neurons
Tumor-like cells at the site
of graft
Cai et al. [108]
Rat 6-OHDA PD patient iPSC-
derived DA neurons Transplantation Improved motor behavior Hargus et al.
[109]
Rat 6-OHDA iPSC-derived DA
neurons Transplantation Improved motor behavior Wernig et al.
[110]
Rat 6-OHDA iPSC-derived DA
neurons Transplantation Improved motor behavior Swistowski et al.
[19]
Stroke
Rat MCAO iPSCs + FG
Direct injection to
infarct
area/subdural
Decreased infarct size
Improved motor
performance
Decreased inﬂammatory
cytokines
Chen et al. [111]
Mouse MCAO Mouse iPSCs Transplantation Tridermal tumorigenesis Kawai et al.
[112]
Mouse MCAO Mouse iPSCs Transplantation
Increased teratoma risk
and volume
Increased MMP9 and
pVEGFR2
Yamashita et al.
[113]
SCI Mouse Contusion model iPSC-derived
neurospheres
Transplantation
(contusion area)
Remyelination and
functional recovery Tsuji et al. [114]
6-hydroxydopamine (6-OHDA), dopaminergic (DA), ﬁbrin glue (FG), induced-pluripotent stem cell (iPSC), matrix metalloproteinase-9 (MMP9), midbrain
(mb), middle cerebral artery occlusion (MCAO), Parkinson’s disease (PD), phosphorylated vascular endothelial growth factor receptor2 (pVEGFR2),
progenitor cell (PGC), and spinal cord injury (SCI).
groups have reported the beneﬁcial eﬀect of iPSCs trans-
plantation on behavioral deﬁcits in 6-hydroxydopamine-
(6-OHDA) lesioned rats as evaluated by amphetamine-
andapomorphine-inducedrotationalasymmetry[108–110].
Human iPSC line, PD-speciﬁc iPSCs, or mouse iPSCs
were used in these studies. Transplanted human iPSC-
derived midbrain dopaminergic cells survived long term in
the graft region and gave rise to midbrain dopaminergic
neurons [108]. The PD-speciﬁc iPSC-derived dopaminergic
neuronssurvivedathighnumbers,showedarborization,and
mediated functional eﬀects in 6-OHDA-lesioned rats [109].
However, only a few DA neurons developed projections into
the host striatum at 16wk after transplantation whereas PD-
speciﬁc iPSC-derived nondopaminergic neurons sent axonal
projections to speciﬁc near and remote target areas in the
adult brain. Wernig et al. pursued a diﬀerent strategy and
transplanted mouse iPSC-derived dopaminergic neurons
[110]. The contamination of undiﬀerentiated iPSCs and
subsequent teratoma formation after transplantation was
a major complication that was revealed in this study.
They concluded that the contamination of undiﬀerentiated
cells was the most likely reason viral transcripts were not
detected in teratoma tissues. The risk of tumor forma-
tion from the grafted cells was minimized by separating
contaminating undiﬀerentiated pluripotent cells from com-
mitted neural cells using ﬂuorescence-activated cell sorting
[110]. Following the transplantation of human iPSC-derived
dopaminergic neurons to 6-hydroxydopamine-lesioned rats,
no teratoma formation was observed [19]. These results
suggest the importance of the developmental stage or level
of diﬀerentiation of transplanted cells for the success of cell-
replacement studies.
Despite advances in medical and surgical care, current
clinical therapies for SCI are limited. SCI can aﬀect relatively
youngpeoplewhooftenbecomeahugeburdentothemselves
and society due to high medical costs throughout their
lives. Rationales for therapeutic use of stem cells for SCI
include replacement of damaged neurons and glial cells,
secretion of trophic factors, regulation of gliosis and scar
formation, and enhancement of axon regeneration [14].
However, the availability of clinically suitable cell sources for
human application has been hindered by both technical and
ethicalissues[15].Thepotentialtherapeuticeﬀectofthecell-
replacement by iPSCs in SCI has recently been shown by
Tsuji et al. in mouse spinal contusive injury model [114].
When the authors sorted the safe (without contamination
of undiﬀerentiated iPSCs) iPSC-derived neurospheres and
transplanted them into the mouse spinal cord 9 days after
contusive injury, these cells gave rise to all three neural
lineages without forming teratomas or other tumors.
Furthermore, transplanted cells also contributed to
endogenous remyelination, induced the axonal regeneration
and axonal outgrowth of host serotonergic ﬁbers, and
promoted the recovery of locomotor function. In contrast
to this, the transplantation of iPSC-derived neurospheres
sorted as unsafe exhibited teratoma formation and even hadStem Cells International 11
detrimental eﬀects on the functional recovery following SCI
[114]. The therapeutic potential of iPSCs in traumatic brain
injury remains unexplored.
Acute stroke is the second or third most common cause
of death and the primary cause of morbidity and long-term
neurological disability worldwide. The only FDA-approved
treatment for stroke is the use of the thrombolytic agent,
tissue-plasminogen activator. This therapy is very limited
due to a narrow therapeutic time window and the risk of
hemorrhagic complications. The regeneration of the brain
after damage is active even weeks after stroke occurs, which
might provide a rational for cell-replacement therapy [116].
Transplantationofstemcellsorstemcell-derivedprogenitors
has long been seen as a therapeutic solution to repair
the damaged brain and shown to be safe and eﬀective
in ischemic stroke animal models. However, conclusive
evidenceinpatientsisstilllacking.Asonlysmallrandomized
controlled trials with ischemic stroke patients exist. Thus, it
is too early to know whether stem cell transplantation can
improve the functional outcome and comprehensive, well-
designed trials are needed [10]. The derivation of human
iPSCs may oﬀer a new possibility for cell-based therapies
of stroke-induced brain damage. In a rat stroke model
(middle cerebral artery occlusion), Chen et al. showed that
the direct injection of iPSCs into damaged areas of rat cortex
signiﬁcantly decreased the infarct size and improved the
motor function as evaluated by the animals performance
in rotarod and grasping tasks [111]. Furthermore, subdural
transplantation of iPSCs mixed with ﬁbrin glue as a less
invasive delivery route could also eﬀectively reduce the total
infarct volume and greatly improve the behavior of cerebral
ischemic rats. This treatment regime also had positive eﬀects
on attenuating inﬂammatory cytokine expression due to
cerebral ischemia. However, contrary results were obtained
in another study using a similar cerebral ischemia model in
mice, which was not able to show any beneﬁcial eﬀect of
mouse iPSC transplantation [112].
Moreover, transplanted undiﬀerentiated iPSCs formed
tridermal tumorigenesis in ischemic mouse brain, sug-
gesting a facilitating and promoting eﬀect of the postis-
chemic microenvironment for the development of tumors.
IPSCs grafted into ischemic brains formed teratoma with
higher probability and larger volume as compared to those
formed in intact brain tissue. The expression of matrix
metalloproteinase-9 and phosphorylated vascular endothe-
lial growth factor receptor2 are signiﬁcantly increased in
iPSC-derivedtumorsintheischemicmousebrain[113].The
eﬀect of postischemic microenvironment on tumorigenesis
may be speciﬁc to the diﬀerentiation status of transplanted
cells similar to those shown for hESC-derived NPCs [118].
These results suggest that the safety of iPSCs should be
critically evaluated not only under normal condition, but
also in speciﬁc pathological conditions such as experimental
cerebralischemia.Daadietal.showedthepotentialofhuman
ESC-derivedNSCsinaneonatalbrainhypoxiaanimalmodel
[119]. Hypoxic-ischemic brain injury in newborn infants is
a major cause for cerebral palsy, neurological disability, and
epilepsy. Stem cell-based therapy has the potential to rescue
and replace the ischemic tissue caused by hypoxic-ischemic
injury and to restore function of the nervous system [120].
The relevance of these ﬁndings for the use of iPSCs remains
to be studied. The generation of iPSCs from human neonatal
tissues may oﬀer a promising cell source for cell-replacement
therapy in infants [121].
7.LimitationsofiPSCTechnology
7.1. Limitations of Generating of iPSC. As outlined above, the
major limitation of iPSC-based therapies is its tumorigenic
potential. Current diﬀerentiation methods are not eﬃcient
enough to transform all iPSCs, and undiﬀerentiated cells
remain in the preparation [110, 122, 123]. This problem can
be overcame by designing positive-negative selection using
ﬂuorescent-activated cell sorting (FACS) or drug selection
approaches [114].
Most patient-speciﬁc iPSCs have been generated by
lentiviruses or retroviruses containing reprogramming fac-
tors,whichbothleadtogenomicintegrationofthetransgene
a n dw h i c hm a yn o tg e ts i l e n c e de ﬃciently at the pluripotent
stage. Moreover, reactivation of the silenced transgenes can
cause undesirable side eﬀects in reprogrammed cells. Thus,
avoiding genomic integration may be a crucial step in the
derivation of safe iPSCs for cell replacement therapy and
can be achieved by improving transgene-free or nonviral
methods [124, 125].
Several groups put considerable eﬀort in working out
nonviral delivery methods, such as using chemicals that can
improveeﬃciencyinordertoderiveiPSCs[52,70,126,127].
One of these studies showed that a chemical approach could
signiﬁcantly improve (200-fold) the eﬃciency of viral iPSC
generation from human ﬁbroblasts therefore providing a
way towards the development of safer, more eﬃcient, and
nonviral methods for reprogramming human somatic cells
[128].
For regenerative medicine, human iPSCs and hESCs are
promising cell sources. They have the common ability to
diﬀerentiate into all three germ layers; however, one recent
study revealed that heterogeneity in gene expression levels
is much greater among hiPSCs than among hESCs. It is
also suggested that human iPSCs occupy an alternate and
less stable pluripotent state. Moreover, human iPSCs display
slower growth kinetics and impaired directed diﬀerentiation
when compared to hESCs [129].
According to recent studies, many mouse iPSCs are also
prone to epigenetic abnormalities and sustain a transient
epigeneticmemoryoftheirdonorcells[130,131].Therefore,
together with development of optimized diﬀerentiation
methods, a careful analysis of genomic and epigenetic
integrity of human iPSCs is required for generating homoge-
nous adult-like cells capable of in vivo function. In addition,
the variability that has long been observed between diﬀerent
humanESClinescanbeevenmoredramaticinhumaniPSCs
because of their diverse origins and the diﬀerent modes of
derivation [132]. Thus, variability between human iPSCs
requires the development of speciﬁc protocols for nearly
every iPSC line generated. In two recent studies, neurons
were generated from ﬁbroblasts by directed reprogramming
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addition to cell reprogramming without reversion to a
pluripotent stem cell state, in vivo reprogramming has also
been reported [135]. Thus, a better understanding of the
mechanisms controlling reprogramming of somatic cells
such as transdiﬀerentiation bears the potential for faster and
widerpracticalapplicationsincelltherapythaniPSCsmight.
Another challenge of iPSC technology is that the process
of well-characterized and carefully validated iPSC line gen-
eration is a time-consuming process. The lag between the
initiation of reprogramming and cell delivery to a patient
might render the process inappropriate for therapeutic
applications, for instance in acute organ failure or injury
[124].
In addition to the diﬃculty of isolating the optimal
cell type that has the best potential for transplantation,
poor survival rates, limited self-renewal, and limited hom-
ing/migrationaftertransplantationshouldbetakenintocon-
sideration to improve iPSCs based-approaches [136, 137].
7.2. Clinical Limitations of iPSCs in Neurological Disorders.
IPSCscell-basedtherapiesarestillintheirinfancy.Therefore,
numeroushurdlesmustbeovercomebeforetheycanbeused
in clinical applications.
So far, iPSCs technology has been used to investi-
gate monogenetic neurodegenerative diseases and some
promising data have been published providing a new way
to understand the pathology of the diseases. However,
multifactorial neurodegenerative disease modeling has not
been performed yet. One of the questions concerning iPSC-
based disease modelling is whether late-onset diseases like
AD and PD can be eﬃciently recapitulated in vitro within
a few days of cell culture or whether the exposure to
diﬀerent types of environmental factors or genetic stress
to the cells is necessary for revealing the desired disease
phenotype. One study related to PD showed that iPSCs
derived from sporadic PD patients do not display apparent
abnormalities when compared with wildtype neurons [62].
Most of the neurodegenerative diseases develop in a noncell-
autonomous manner requiring the interaction of diﬀerent
cell types [4, 138]. Recent ﬁndings indicate that astrocytes
may play a role in the speciﬁc degeneration of spinal
motor neurons in ALS [139, 140]. The eﬀect of diﬀerent
cell types on disease development were studied in mouse
and human ALS models. ESCs were engineered to carry
ALS-speciﬁc SOD1 mutation and diﬀerentiated into both
motor neurons and astrocytes that were supposed to interact
during disease development. The coculture of both cells
types caused a prominent cell death in motor neurons
indicating that astrocytes contribute to the pathophysiology
of ALS [141–143]. Noncell autonomous mechanisms have
also been implicated in other neurodegenerative disorders
such as spinocerebellar ataxia [144, 145]. Thus, eﬃcient
coculture systems should be developed to test for these
eﬀects. However, current technologies for diﬀerentiation of
iPSCs are limited to a few functional cell types and are not
very eﬃcient. In neurodegenerative disease modeling from
iPSCs, genetic information, environment, and senescence
all take part in the neurodegeneration process and thus
achieving relevant conditions in vitro would be crucial.
8.FutureProspects
Despite a large body of current research, iPSC technology is
still in its infancy. There are many limitations that have to
be solved before clinical trials for treatment of neurological
disorders can be performed. For monogenic diseases, which
require gene targeting to repair mutant alleles, new targeting
strategies need to be developed concomitantly [100]. A
recentstudyreportedthattheuseofzinc-ﬁngernucleasescan
correct genetic defect by homologous recombination with
high eﬃciency in iPSCs and hESCs [146]a n dm a yb ea n
appropriate and eﬃcient method for correction of genetic
defect in human cells.
IPSCs technology needs to be standardized in order to
create medically relevant cells. For the translation of iPSCs
into therapeutics and human clinical applications, current
good manufacturing practices (cGMP) will also be necessary
[106]. The scientiﬁc community, the government, and/or
private organizations are responsible for the implementation
of guidelines. This is essential to accelerate the global
movement towards safer iPSCs in an academic, clinical, or
private sector.
So far, most of the iPSCs lines have been exposed to
animalproductseitherindirectorindirectways,whichcould
make these cells improper for transplantation.
Therefore, cGMP standards have to construct standard-
ized animal-free methods for the derivation of iPSC lines
[106]. Human iPSCs can be generated under serum and
feeder cell-free conditions bringing iPSCs an important step
closer to clinical applications [21, 147].
An alternative to the feeder cell-free culture method has
been established by using autologous skin ﬁbroblasts derived
from the same patient, which provides an appropriate source
of feeder cells [148, 149]. Additionally, as well as devel-
oping serum/feeder-free conditions and autogenic feeder
cells, eﬀective cryopreservation procedures are essential to
facilitate cell banking for future applications [150].
Nonviral and transgene-free reprogramming methods
have been signiﬁcantly improved, yet the cancer-causing
potential of safe iPSCs still needs to be evaluated in animal
models before clinical applications in humans. Besides small
animals such as mice and rats, iPSC therapies need to be
validated in large animal models which are anatomically
and physiologically more relevant to humans. IPSCs have
been generated from monkeys [151–153] and pigs [154,
155] which are better models for preclinical transplantation
studies.
The safety and eﬃcacy of cell-based therapies for neu-
rodegenerative diseases also depend on the method of cell
administration. One study has suggested that intranasally
administered cells could pass through the blood-brain bar-
rier [156, 157]. Therefore, this kind of noninvasive methods
for cell delivery to the CNS needs to be further explored for
iPSCs.
9. Conclusion
Since the ﬁrst generation of human iPSCs, a large number
of patient-speciﬁc iPSC lines have been developed. Recently,Stem Cells International 13
iPSC studies have exploded and the potential application of
these cells in establishing disease models, drug screening,
and cell transplantation-based therapy have been widely
recognized. IPSCs have distinct advantages over hESC such
as the lack of ethical restrictions and immune rejection
of the graft. In addition to their direct therapeutic use in
cell replacement therapy, disease modeling is most likely
the most important aspect of iPSC technology. IPSCs are
the patient’s own cells and therefore the best possible
source for cell transplantation treatment provided that
their genetic program can be changed for the treatment
of neurodegenerative diseases. Human iPSCs hold great
promise for the treatment of incurable neurodevelopmental
and neurodegenerative diseases. Furthermore, iPSC-based
cell therapy may contribute to neurorepair in the chronic
phase of acute CNS injuries such as stroke and neurotrauma.
However, iPSC technology still faces speciﬁc diﬃculties such
as low eﬃciency and high variability. Finally, iPSC-based
therapeutic strategies need to be evaluated in preclinical
animal models of neurological diseases before clinical trials.
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